Moderna’s teen COVID-19 vaccine trial hits high marks

The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and older in a couple of weeks.

| More on:
medical researcher holding laboratory equipment

Image source: Getty Images.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Tuesday, Moderna (NASDAQ: MRNA) reported highly successful results from a clinical trial of its COVID-19 vaccine in patients ages 12 to 17. Depending on how you look at the top-line data from the TeenCove study, mRNA-1273 was found to be between 93% and 100% effective at preventing new cases.

The TeenCOVE trial enrolled over 3,700 12- to 17-year-old participants. Going by the primary case definition of COVID-19, from a period starting 14 days after their second dose, none of the volunteers who received the vaccine have tested positive. And although new case numbers are plummeting across the country, four of the volunteers who received the placebo did test positive for COVID-19.

Since teenagers are far less likely to present symptoms of COVID-19 when they're infected, investigators also used a more sensitive definition of COVID-19 positivity that requires just one symptom plus a positive nasal swab test. Based on those looser criteria, the vaccine was still 93% effective at preventing new cases.

The TeenCove trial results Moderna reported Tuesday stack up nicely against those reported in March by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) for their rival mRNA vaccine, Comirnaty. That said, comparisons between the two teen trials should be taken with a grain of salt. Pfizer and BioNTech ran their U.S.-based clinical trial in 12- to 15-year-olds at a time when far more Americans were contracting the virus.

Moderna plans to submit a completed data package from the TeenCOVE study to the FDA in early June. Given that its top-line results are roughly in line with those that earned Pfizer and BioNTech a green light for their vaccine to be administered to teens, we can reasonably expect a similar response from the regulator within a few days of its receiving Moderna's submission.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

More on International Stock News